Bibliographic Details
| Title: |
Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. |
| Authors: |
Clark PE; Atrium Health Carolinas Medical Center, Wake Forest School of Medicine, Charlotte, NC, USA. Electronic address: peter.clark@wfusm.edu. |
| Source: |
European urology [Eur Urol] 2026 Feb 25. Date of Electronic Publication: 2026 Feb 25. |
| Publication Type: |
Journal Article |
| Journal Info: |
Publisher: Elsevier Science Country of Publication: Switzerland NLM ID: 7512719 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7560 (Electronic) Linking ISSN: 03022838 NLM ISO Abbreviation: Eur Urol Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
